Hypoglycaemia in Clinical Diabetes

REFERENCES 259Fanelli C, Pampanelli S, Epifano L, Rambotti AM, Ciofetta M, Modarelli F et al. (1994). Relativeroles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of anddeterioration of cognitive function in hypoglycaemia in male and female humans. Diabetologia 37:797–807.Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A et al. (2003). Effect on glycemiccontrol of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatmentin patients with type 2 diabetes. Diabetes Care 26: 2370–7.Fink RI, Revers RR, Kolterman OG, Olefsky JM (1985). The metabolic clearance of insulin and thefeedback inhibition of insulin secretion are altered with ageing. Diabetes 34: 275–80.Gold AE, MacLeod KM, Frier BM (1994). Frequency of severe hypoglycemia in patients with type 1diabetes with impaired awareness of hypoglycemia. Diabetes Care 17: 697–703.Goudswaard A, Furlong NJ, Rutten G, Stolk R, Valk G (2004). Insulin monotherapy versus combinationsof insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus (Cochranereview). Cochrane Database of Systematic Reviews 4: CD003418.Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W (2005). Lower within-subject variability offasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin inpatients with type 2 diabetes. Diabetes Obesity and Metabolism 7: 56–64.Harrigan RA, Nathan MS, Beattie P (2001). Oral agents for the treatment of type 2 diabetes mellitus:pharmacology, toxicity and treatment. Annals of Emergency Medicine 38: 68–78.Harrower A (2000). Gliclazide modified release: from once-daily administration to 24-hour bloodglucose control. Metabolism 49 (Suppl 2): 7–11.Hartling SG, Faber OK, Wegmann M-L, Wahlin-Boll E, Melander A (1987). Interaction of ethanoland glipizide in humans. Diabetes Care 10: 683–6.Hay LC, Wilmhurst EG, Fulcher G (2003). Unrecognized hypo- and hyperglycemia in well-controlledpatients with type 2 diabetes mellitus: the results of continuous glucose monitoring. DiabetesTechnology and Therapeutics 5: 19–26.Heller SR, Macdonald IA, Tattersall RB (1987). Counterregulation in type II (non-insulin-dependent)diabetes mellitus. Normal endocrine and glycaemic responses up to 10 years after diagnosis.Diabetologia 30: 924–9.Henderson JN, Allen KV, Deary IJ, Frier BM (2003). Hypoglycaemia in insulin-treated type 2 diabetes:frequency, symptoms and impaired awareness. Diabetic Medicine 20: 1016–21.Hepburn DA, MacLeod KM, Pell ACH, Scougal IJ, Frier BM (1993). Frequency and symptoms ofhypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabetic Medicine10: 231–7.Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, AL Harthi A et al. (2005). A clinical trial ofcontinuous subcutaneous insulin infusion versus multiple daily injections in older adults with type2 diabetes. Diabetes Care 28: 1568–73.Hermansen K, Ronnemaa T, Petersen AH, Bellaire S, Adamson U (2004). Intensive therapy withinhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trialin patients with type 2 diabetes. Diabetes Care 27: 162–7.Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P, on behalf of the LevemirTreat-To-Target Group (2006). A 26-week, randomised, parallel, treat-to-target trial comparinginsulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïvepeople with type 2 diabetes. Diabetes Care 29: 1269–74.Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS et al., for theExubera Phase III Study Group (2004). Efficacy and safety of inhaled insulin (Exubera)compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care 27:2356–62.Holstein A, Plaschke A, Egberts E-H (2001). Lower incidence of severe hypoglycemia in patients withtype 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metabolism Research andReviews 17: 467–73.